Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Regeneron Pharmaceuticals announced on Monday that it will acquire “substantially all” of genetic testing company 23andMe’s assets. The pharmaceutical company said it won the court-supervised auction of the genetic testing…

